Cargando…
Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo
Cisplatin is a commonly used chemotherapeutic drug for treatment of oral carcinoma, and combinatorial effects are expected to exert greater therapeutic efficacy compared with monotherapy. Poly(ADP-ribosyl)ation is reported to be involved in a variety of cellular processes, such as DNA repair, cell d...
Autores principales: | Yasukawa, Masaaki, Fujihara, Hisako, Fujimori, Hiroaki, Kawaguchi, Koji, Yamada, Hiroyuki, Nakayama, Ryoko, Yamamoto, Nanami, Kishi, Yuta, Hamada, Yoshiki, Masutani, Mitsuko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813136/ https://www.ncbi.nlm.nih.gov/pubmed/26927065 http://dx.doi.org/10.3390/ijms17030272 |
Ejemplares similares
-
Possible Action of Olaparib for Preventing Invasion of Oral Squamous Cell Carcinoma In Vitro and In Vivo
por: Nakamura, Nanami, et al.
Publicado: (2022) -
PARP Inhibitor PJ34 Suppresses Osteogenic Differentiation in Mouse Mesenchymal Stem Cells by Modulating BMP-2 Signaling Pathway
por: Kishi, Yuta, et al.
Publicado: (2015) -
Detection accuracy for epithelial dysplasia using an objective autofluorescence visualization method based on the luminance ratio
por: Yamamoto, Nanami, et al.
Publicado: (2017) -
Spontaneous Development of Dental Dysplasia in Aged Parp-1 Knockout Mice
por: Fujihara, Hisako, et al.
Publicado: (2019) -
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)